

## **Author Index for Volume 17**

AASK Pilot Study Investigators, xii, 17(4S):1S, 17(4S):3S, 17(4S):17S, 17(4S):34S, 17(4S):40S, 17(4S):47S Agodoa LY 17(4S):1S, 17(4S):3S Ahern DK, 46 Akiyama T, 294 Anderson G, 509 Anderson IL, 17(3S):17S Anderson MM, Jr, 407 Antman EM, 357 Ash A, 177

Backhouse M, 304 Bailey G, 23, 271 Ballantyne CM, 550 Bandai Y, 476 Bartholow B, 209 Beck RW, 407 Begg CB, 176 Bell L, 304 Berkey CS, 357 Berlin JA, 191 Bigger JT, Jr, 46 Boissel J-P, 130 Bossard N, 130 Bradham KH, 33 Branyon M, 46 Brookmeyer R, 75 Brown BW, 266 Brown L, 536 Buchbinder S, 209 Budeiri D, 60 Burek K, 226 Buxton AE, 17(3S):47S Buxton M, 304 Byington RP, 33

Camm AJ, 17(3S):4S Campion J, 46 Campos-Perez Y, 258 Cantor AB, 111 Carmody S, 23, 271 Carranza-Madrigal J, 258 Carroll D, 1 Catalano PM, 442 Chamberlain RM, 494 Charleston J, 17(4S):17S, 17(4S):47S Chavez-Carbajal F, 258 Clemens JD, 442 Cole T, 536 Cornell CE, 17(4S):40S Cottinghan V, 23, 271 Crow S, 415 Crowley J, 353 Curet LB, 442

Davidson C, 117
Davidson GK, 117
Davis BR, 536
DeBruge J, 17(4S):17S
DeMets D, 509
DerSimonian R, 442
Diehl Boly L, 407
Digitalis Investigation
Group, 77
Dolecek TA, 33
Dornan JC, 60
Douglas JM, Jr, 209
Douglas M, 17(4S):17S,
17(4S):34S
Duggan J, 46

Edwards JS, 117
Egan D, 23, 271
Eisenberg JM, 304
Elizur-Leiberman E, 201
Ellenberg SS, 354
Engin K, 316
Espeland MA, 33
Estacio RO, 242
Esterlitz JR, 442
Ewell MG, 442

Faille C, 415
Faulkner M, 17(4S):17S, 17(4S):40S, 17(4S):47S
Fisher LD, 423
Fogoros RN, 17(3S):37S
Follick MJ, 46
Fowler G, 235
Freedman L, 509

Friedman SA, 442

Gavaghan DJ, 1
Gibson D, 71
Glasscock R, 17(4S):1S,
17(4S):3S
Glick H, 304
Goldenberg RL, 442
Gorkin L, 46
Gotto AM, Jr, 550
Gøtzsche PC, 285
Gray S, 235
Greene PG, 17(4S):17S,
17(4S):34,
17(4S):40
Greenhouse SW, 474
Grim C, 17(4S):34S

Haakenson C, 294 Hallstrom A, 294 Handshaw K, 46 Hankin B, 415 Harvey A, 71 Hauschke D, 347 Hauth JC, 442 Hawkins CM, 536 Hayashi K, 99 Hennessy M, 209 Herd JA, 550 Herrera-Abaraca JE, 258 Hershey N, 183 Hertert S, 23, 271 Hoen H, 33 Holme I, 13 Hjorth M, 372 Hoaglin DC, 435 Holmberg E, 372 Hudmon KS, 494

Jacobson S-L, 442 Jadad AR, 1 Jenkinson C, 1 Joffe GM, 442 Johnson Nagel N, 242 Johnson P, 23, 271 Jones CA, 17(4S):17S Judson F, 209

Kadane JB, 352

Kakizoe T, 476	MacQueen K, 209	Savage S, 242
Kappelle LJ, 33	Margitic SE, 33	Schemper M, 343
Kiefer S, 17(4S):17S	McKirnan DJ, 209	Schrier RW, 242
Kinney MR, 46	McQuay HJ, 1	
	Meinert CL, 273	Schron EB, 46
Kipnis V, 509	Meisner M, 387	Schulman KA, 304
Kirk KA, 17(4S):1S,		Sculpher M, 304
17(4S):3S,	Milligan S, 17(4S):34S,	Shea S, 46
17(4S):17S,	17(4S):40S,	Sheon A, 209
17(4S):34S	17(4S):47S	Sibai BM, 442
Kiuchi T, 476	Moore RA, 1	Siegel C, 387
Klebanoff MA, 442	Morris CD, 442	Silagy C, 235
Knatterud GL, 290, 4	37, Mosteller F, 356	Simon R, 526
473	Moyé LA, 537	
Konishi M, 476		Simpson S, 550
Kopple JD 17(4S) 409	Naydeck BL, 226	Smith DE, 17(4S):17S,
	Ness RB, 191	17(4S):34S,
Korn EL, 526	Ng T-H, 349	17(4S):40S
Kosuge T, 476	Norris K, 17(4S):17S,	Smith TL, 343
Kusek JW, 17(4S):1S,	17(4S): <b>4</b> 7S	Sopko GS, 226
17(4S):3S,		Steinbach G, 494
17(4S):17S,	Ohashi Y, 476	Steinijans VW, 347
17(4S):34S,	O'Rourke K, 69, 350	Stoltzfus C, 494
17(4S):40S,		Stylianou M, 46
17(4S):47S	Parmar M, 71	•
	Pater J, 548	Suchanek Hudmon K, 495
Lamborn KR, 547	Petrulis AS, 442	Sun H, 268
Lancaster S, 46	Pilpel D, 201	Sutton-Tyrrell K, 226, 415
Lancaster T, 235	Pocock SJ, 292	Sylvia SC, 46
Laska E, 387	Powers SN, 17(4S):17S	
Lau J, 357	Pownall HJ, 550	Taube A, 372
-	Prentice R, 509	Terranova R, 123
Law MG, 221	D 1 (C - 1 .) I 00 071	Toto RD, 17(4S):3S
LCAS Investigators,	Prystowsky EN,	Trudel J, 415
Leavitt FJ, 201	17(3S):1S,	Trader J, 110
Lee JY, 17(4S):1S,	17(3S):28S	Mallon AM 00
17(4S):3S,	17 (55).265	Walker AM, 99
17(4S):17S,	Randall OS, 17(4S):3S	Wang CY, 509
17(4S):34S,	Raymond EG, 442	Ward H, 17(4S):17S
17(4S):40S,	Retta TM, 17(4S):17S	West MS, 550
17(4S):47S		Westin J, 372
Levell B, 17(4S):17S,	Reynolds DJM, 1	Whelton PK, 17(4S):17S,
17(4S):46S	Rigau-Perez JG, 442	17(4S) 34S
Levine RJ, 442	Rödjer S, 372	Williams GW, 72
Li N, 268	Rossouw J, 509	Winn RJ, 494
	Cooks E E26	Wittes J, 509
Li Wan Po A, 60	Sacks F, 536	Wright JT, 17(4S):1S
Lorimor RJ, 494	Salazar LA, 258	0
Luca S, 123	Sather MR, 294	Wright JT, Jr, 17(4S):3S



## **Subject Index for Volume 17**

#### **AASK PILOT STUDY**

Appointment Attendance, Pill Counts, and Achievement of Goal Blood Pressure in the African American Study of Kidney Disease and Hypertension Pilot Study, 17(4S):34S

Design and Baseline Characteristics of Participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):3S

Effect of Blood Pressure Control and Antihypertensive Drug Regimen on Quality of Life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):40S

Overview, 17(4S):1S
Participant Satisfaction in the African
American Study of Kidney
Disease and Hypertension

(AASK) Pilot Study, 17(4S):47S Recruitment Experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):17S

## ACTIVE CONTROL EQUIVALENCE STUDIES

A Note On Conventional Null Hypothesis Testing in Active Control Equivalence Studies (letter), 347, (letter reply), 349

#### ADVERSE DRUG EXPERIENCES

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

#### **AMIODARONE**

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrythmias, 17(3S):37S

#### **ANGIOGRAPHY**

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

## **ANTIARRHYTHMIC AGENTS**

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

## ANTIVIRAL DRUG

Preliminary Results of Beta-Interferon Treatment in the Elderly, 123

#### **ATHEROSCLEROSIS**

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992–1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

#### **AUDITS**

Do Low Observed Error Rates Lessen the Need for Study- Specific Data Quality Audits (letter)?, 69 Response to O'Rourke (letter), 71

# AUTONOMY OF DOCTORS AND PATIENTS

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

## **BASAL NOCTURNAL SECRETION**

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

#### **BAYESIAN ANALYSIS**

Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423

#### **BETA BLOCKERS**

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

#### **BINARY DATA**

Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

#### **BIOLOGY**

Biological Rationale and Clinical Experience with Hyperthermia, 316

#### **BIOMETRY**

Case Studies in Biometry (book review), 266

## **BLINDING ANALYSES**

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

Blinding During Data Analysis and Writing of Manuscripts, 285

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

## BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION (BARI)

Organizational Structure and
Communication Strategies of the
Bypass Angioplasty
Revascularization Investigation: A
Multicenter Clinical Trial, 226

#### **CALCIUM**

Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods (design paper), 442

## **CANCER PREVENTION**

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 495

#### CANCER TREATMENT

Biological Rationale and Clinical Experience with Hyperthermia, 316

## CARDIAC ARRHYTHMIA

Clinical Trial Enrollers vs. Nonenrollers:
The Cardiac Arrhythmia
Suppression Trial (Cast)
Recruitment and Enrollment
Assessment in Clinical Trials
(REACT) Project, 46

Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrythmias, 17(3S):37S

Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S

## **CASE STUDIES**

Case Studies in Biometry (book review), 266

## CAST

Clinical Trial Enrollers vs. Nonenrollers:
The Cardiac Arrhythmia
Suppression Trial (Cast)
Recruitment and Enrollment
Assessment in Clinical Trials
(REACT) Project, 46

## **CHEMOPREVENTION**

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 494

#### CHOLESTEROL

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550
Maximizing Recruitment Efforts in a
Drug Lipid-Lowering Trial with

Dietary Intervention to Lower LDL Cholesterol, 33

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

## CHRONIC VIRAL LIVER DISEASE

Preliminary Results of Beta-Interferon Treatment in the Elderly, 123

#### **CLINICAL DECISION MAKING**

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

#### **CLINICAL EFFECTIVENESS**

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

## CLINICAL INVESTIGATOR

The Clinical Investigator as Target, 183

#### CLINICAL MEASUREMENT

Clinical Measurement in Drug Evaluation (book review), 354

## **CLINICAL TRIAL REGISTRY**

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992–1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

#### **CLINICAL TRIALS**

Analyzing Survival Data from Clinical Trials and Observational Studies (book review), 353

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast) Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46

Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S

Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423

Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415

Community Volunteers as Recruitment
Staff in a Clinical Trial: The
Systolic Hypertension in the
Elderly Program (SHEP)
Experience, 23

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526

Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 537

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209

Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrythmias, 17(3S):37S

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S

Organizational Structure and
Communication Strategies of the
Bypass Angioplasty
Revascularization Investigation: A
Multicenter Clinical Trial, 226

- Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 494
- Physicians' Attitudes Toward Clinical Trials and Their Relationship to Patient Accrual in a Nordic Multicenter Study on Myeloma, 372
- Planning Pharmaceutical Clinical Trials (book review), 73
- Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S
- Recent Advances in Clinical Trial Design and Analysis (book review), 547
- Quality of Life and Pharmacoeconomics in clinical Trials (book review), 548
- Registry of Multicenter Clinical Trials:
  14th and 15th Report 1992–1993.
  On Behalf of the Council on
  Thrombosis and Haemostasis of
  the International Society and
  Federation of Cardiology, and
  the Scientific and Standardization
  Committee of the International
  Society on Thrombosis and
  Haemostasis, 130
- Statistics in Medical Research: Developments in Clinical Trials (book review), 176
- Sudden Cardiac Death: Lessons from Multicenter Clinical Trials, 17(3S):1S
- Thomas C. Chalmers, M.D., 474
  Tribute to Dr. Thomas C. Chalmers, 475
  Trial of Calcium for Preeclampsia
  Prevention (CPEP): Rationale,
  Design, and Methods (design
  paper), 442

## **CLOSE-OUT OUESTIONNAIRE**

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 494

#### **COLLABORATIVE RESEARCH**

Exploring Collaborative Research in Primary Care (book review), 177

#### **COMMUNICATION**

- Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415
- Organizational Structure and Communication Strategies of the Bypass Angioplasty

Revascularization Investigation: A Multicenter Clinical Trial, 226

## **COMPUTED TOMOGRAPHY**

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

#### **CONDITIONAL POWER**

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526

## CONFIDENCE LEVEL

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

## **CORONARY DISEASE**

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

#### **COST EFFECTIVENESS ANALYSIS**

- The Economic Avaluation of the FIRST
  Study: Design of a Prospective
  Analysis Alongside a
  Multinational Phase III Clinical
  Trial, 304
- Statistical Methods for Cost-Effectiveness Analyses, 387

#### **CROSS CULTURAL BIOETHICS**

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

## **CUMULATIVE META-ANALYSIS**

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

## **DATA ANALYSIS**

Blinding During Data Analysis and Writing of Manuscripts, 285 Visualizing Data: The New Frontier of Data Analysis (book review), 435

#### **DATA MANAGEMENT**

A World Wide Web-based User Interface for a Data Management System Dietary Intervention to Lower LDL Cholesterol, 33

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

## CHRONIC VIRAL LIVER DISEASE

Preliminary Results of Beta-Interferon Treatment in the Elderly, 123

## **CLINICAL DECISION MAKING**

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

## **CLINICAL EFFECTIVENESS**

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

## CLINICAL INVESTIGATOR

The Clinical Investigator as Target, 183

## CLINICAL MEASUREMENT

Clinical Measurement in Drug Evaluation (book review), 354

#### **CLINICAL TRIAL REGISTRY**

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992–1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

#### **CLINICAL TRIALS**

Analyzing Survival Data from Clinical Trials and Observational Studies (book review), 353

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast) Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46

Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S

Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423

Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526

Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 537

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209

Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrythmias, 17(3S):37S

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S

Organizational Structure and
Communication Strategies of the
Bypass Angioplasty
Revascularization Investigation: A
Multicenter Clinical Trial, 226

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 494

Physicians' Attitudes Toward Clinical Trials and Their Relationship to Patient Accrual in a Nordic Multicenter Study on Myeloma, 372

Planning Pharmaceutical Clinical Trials (book review), 73

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

Recent Advances in Clinical Trial Design and Analysis (book review), 547

Quality of Life and Pharmacoeconomics in clinical Trials (book review), 548

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992–1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

Statistics in Medical Research: Developments in Clinical Trials (book review), 176

Sudden Cardiac Death: Lessons from Multicenter Clinical Trials, 17(3S):1S

Thomas C. Chalmers, M.D., 474
Tribute to Dr. Thomas C. Chalmers, 475
Trial of Calcium for Preeclampsia
Prevention (CPEP): Rationale,
Design, and Methods (design
paper), 442

## **CLOSE-OUT QUESTIONNAIRE**

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 494

#### **COLLABORATIVE RESEARCH**

Exploring Collaborative Research in Primary Care (book review), 177

#### **COMMUNICATION**

Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415

Organizational Structure and Communication Strategies of the Bypass Angioplasty Revascularization Investigation: A Multicenter Clinical Trial, 226

#### COMPUTED TOMOGRAPHY

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

#### **CONDITIONAL POWER**

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526

#### CONFIDENCE LEVEL

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

#### **CORONARY DISEASE**

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

## **COST EFFECTIVENESS ANALYSIS**

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

Statistical Methods for Cost-Effectiveness Analyses, 387

#### **CROSS CULTURAL BIOETHICS**

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

## **CUMULATIVE META-ANALYSIS**

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

## **DATA ANALYSIS**

Blinding During Data Analysis and Writing of Manuscripts, 285 Visualizing Data: The New Frontier of Data Analysis (book review), 435

#### **DATA MANAGEMENT**

A World Wide Web-based User Interface for a Data Management System for Use in Multi-institutional Clinical Trials—Development and Experimental Operation of an Automated Patient Registration and Random Allocation System, 476

#### **DATA MONITORING**

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 527

#### **DATA QUALITY**

Do Low Observed Error Rates Lessen the Need for Study- Specific Data Quality Audits (letter)?, 69

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

Response to O'Rourke (letter), 71

#### **DESIGN**

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

# DIABETES, NON-INSULIN DEPENDENT

Baseline Characteristics of Participants in the Appropriate Blood Pressure Control in Diabetes Trial, 242

#### DIAGNOSTIC UNCERTAINTY

Randomized Clinical Trials in the Presence of Diagnostic Uncertainty: Implications for Measures of Efficacy and Sample Size, 191

#### **DICLOFENAC**

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

#### DIET

Maximizing Recruitment Efforts in a

Drug Lipid-Lowering Trial with Dietary Intervention to Lower LDL Cholesterol, 33

## **DIGOXIN**

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

#### **DISEASE PREVENTION**

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

## **DOUBLE MASKING**

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

## DRUG EVALUATION

Clinical Measurement in Drug Evaluation (book review), 354

## EARLIEST CUMULATIVE SIGNIFICANCE

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

#### **ECONOMICS**

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

#### **ELDERLY POPULATIONS**

Forecasting the Health of Elderly Populations (book review), 75 Preliminary Results of Beta-Interferon Treatment in the Elderly, 123

## END-STAGE RENAL DISEASE Overview, 17(4S):1S

#### **ENROLLMENT**

Clinical Trial Enrollers vs. Nonenrollers:
The Cardiac Arrhythmia
Suppression Trial (Cast)
Recruitment and Enrollment
Assessment in Clinical Trials
(REACT) Project, 46

## **EPIDEMIOLOGY**

Ethics and Epidemiology and Clinical Research (book review), 437

#### **ERROR RATES**

Do Low Observed Error Rates Lessen the Need for Study-Specific Data Quality Audits (letter)?, 69 Response to O'Rourke (letter), 71

#### **ETHICS**

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

Ethics and Epidemiology and Clinical Research (book review), 437 Tribute to Dr. Thomas C. Chalmers, 473

#### **EVENING PRIMROSE OIL**

Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60

#### **FACTORIAL SURVEY**

A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209

#### **FAILURE TIME**

A Note on Quantifying Follow-up in Studies of Failure Time, 343

## **FIALURIDINE (FIAU)**

An Open Letter to the FDA Regarding Changes in Reporting Procedures for Drugs and Biologics Proposed in the Wake of the FIAU Tragedy (letter), 273

## **FLUVASTATIN**

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

## **FOLLOW-UP**

A Note on Quantifying Follow-up in Studies of Failure Time, 343

#### FOOD AND DRUG ADMINISTRATION (FDA)

An Open Letter to the FDA Regarding Changes in Reporting Procedures for Drugs and Biologics Proposed in the Wake of the FIAU Tragedy (letter), 273

#### **FORECASTING**

Forecasting the Health of Elderly Populations (book review), 75

#### FREQUENTIST ANALYSIS

Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423

#### H2 ANTAGONIST

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

#### HEALTH TECHNOLOGY ASSESSMENT

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

#### **HEART FAILURE**

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

## **HEMOSTASIS**

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992–1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

## HIV

A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209

## HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASES/ ANTAGONISTS AND INHIBITORS

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):

Design, Methods, and Baseline Data of a Trial of Fluvastatin in Patients without Severe Hypercholesterolemia, 550

#### **HYPERTENSION**

Appointment Attendance, Pill Counts, and Achievement of Goal Blood Pressure in the African American Study of Kidney Disease and Hypertension Pilot Study, 17(4S):34S

Baseline Characteristics of Participants in the Appropriate Blood Pressure Control in Diabetes Trial, 242

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271

Comparison of Once Daily and Twice Daily Nisoldipine as Monotherapy in Essential Hypertension, 117

Design and Baseline Characteristics of Participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):3S

Effect of Blood Pressure Control and Antihypertensive Drug Regimen on Quality of Life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):40S

Overview, 17(4S):1S

Participant Satisfaction in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):47S

Recruitment Experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):17S

Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods (design paper), 442

#### **HYPERTHERMIA**

Biological Rationale and Clinical Experience with Hyperthermia, 316

#### **IMPLEMENTATION**

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

## INFORMED CONSENT

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

#### INTENT-TO-TREAT

Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrythmias, 17(3S):37S

Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

#### **INTERIM ANALYSIS**

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526

#### **INTERNET**

A World Wide Web-based User Interface for a Data Management System for Use in Multi-institutional Clinical Trials—Development and Experimental Operation of an Automated Patient Registration and Random Allocation System, 476

#### KAPLAN-MEIER METHOD

Power Calculation for the Log Rank Test Using Historical Data, 111

#### KAPOSI'S SARCOMA

Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

## KIDNEY DISEASE

Appointment Attendance, Pill Counts, and Achievement of Goal Blood Pressure in the African American Study of Kidney Disease and Hypertension Pilot Study, 17(4S):34S

Design and Baseline Characteristics of Participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):3S

Effect of Blood Pressure Control and Antihypertensive Drug Regimen on Quality of Life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):40S

Overview, 17(4S):1S
Participant Satisfaction in the African
American Study of Kidney
Disease and Hypertension
(AASK) Pilot Study, 17(4S):47S

Recruitment Experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):17S

#### LARGE SIMPLE TRIAL

Rationale, Design, Implementation, and
Baseline Characteristics of
Patients in the DIG Trial: A Large,
Simple, Long-Term Trial to
Evaluate the Effect of Digitalis on
Mortality in Heart Failure, 77

## LIPIDS

Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 536

Maximizing Recruitment Efforts in a
Drug Lipid-Lowering Trial with
Dietary Intervention to Lower
LDL Cholesterol, 33

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

#### LOG RANK TEST

Power Calculation for the Log Rank Test Using Historical Data, 111

#### **MANAGEMENT**

Organizational Structure and

Communication Strategies of the Bypass Angioplasty Revascularization Investigation: A Multicenter Clinical Trial, 226

#### MASKING

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

## **MEAL-STIMULATED SECRETION**

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

## MEDICAL RESEARCH

Statistics in Medical Research: Developments in Clinical Trials (book review), 176

#### **META-ANALYSIS**

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

Thomas C. Chalmers, M.D., 474
Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

#### **MONOTHERAPY**

Comparison of Once Daily and Twice Daily Nisoldipine as Monotherapy in Essential Hypertension, 117

## MULTICENTER CLINICAL TRIALS

Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415

Physicians' Attitudes Toward Clinical Trials and Their Relationship to Patient Accrual in a Nordic Multicenter Study on Myeloma, 372

Sudden Cardiac Death: Lessons from

Multicenter Clinical Trials, 17(3S):1S

#### MULTIPLE ENDPOINTS

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

## **MULTIPLE MYELOMA**

Physicians' Attitudes Toward Clinical Trials and Their Relationship to Patient Accrual in a Nordic Multicenter Study on Myeloma, 372

# MULTIVARIATE NORMAL DISTRIBUTION

Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 536

## **MYOCARDIAL INFARCTION**

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

#### **NET BENEFIT**

Statistical Methods for Cost-Effectiveness Analyses, 387

#### **NISOLDIPINE**

Comparison of Once Daily and Twice Daily Nisoldipine as Monotherapy in Essential Hypertension, 117

#### **NON-RESPONDER MODELS**

Statistical Methods for Cost-Effectiveness Analyses, 387

#### **NULL HYPOTHESIS TESTING**

A Note On Conventional Null Hypothesis Testing in Active Control Equivalence Studies (letter), 347, (letter reply), 349

## **OBSERVATIONAL STUDIES**

Analyzing Survival Data from Clinical Trials and Observational Studies (book review), 353

#### **ONCOLOGY**

Biological Rationale and Clinical Experience with Hyperthermia, 316

## ORGANIZATIONAL STRUCTURE

Organizational Structure and
Communication Strategies of the
Bypass Angioplasty
Revascularization Investigation: A
Multicenter Clinical Trial, 226

#### **OVERVIEW**

Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

#### PAIN

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

#### PARTICIPANT PERCEPTIONS

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 494

#### PATIENT ACCRUAL

Physicians' Attitudes Toward Clinical Trials and Their Relationship to Patient Accrual in a Nordic Multicenter Study on Myeloma, 372

#### PATIENT CONTACT

Remote Clinic/Patient Monitoring for Multicenter Trials, 407

#### **PEDIATRICS**

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

### PENTAGASTRIN TEST

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

## **PHARMACEUTICALS**

Planning Pharmaceutical Clinical Trials (book review), 73

## **PHARMACOECONOMICS**

Quality of Life and Pharmacoeconomics in clinical Trials (book review), 548

## **PHARMACOEPIDEMIOLOGY**

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

#### **PHARMACOKINETICS**

Pharmacokinetics: Regulatory-Industrial-Academic Perspectives (book review), 268

## PHONE CERTIFICATION/ RECERTIFICATION

Remote Clinic/Patient Monitoring for Multicenter Trials, 407

## PHYSICIANS' ATTITUDES

Physicians' Attitudes Toward Clinical Trials and Their Relationship to Patient Accrual in a Nordic Multicenter Study on Myeloma, 372

#### **PLACEBO**

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

#### **POWER**

Power Calculation for the Log Rank Test Using Historical Data, 111

## **PREECLAMPSIA**

Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods (design paper), 442

## PREFERENCE MEASURES

Statistical Methods for Cost-Effectiveness Analyses, 387

## **PREGNANCY**

Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods (design paper), 442

## PREMENSTRUAL SYNDROME

Is Evening Primrose Oil of Value in the

Treatment of Premenstrual Syndrome?, 60

## PRIMARY CARE

Exploring Collaborative Research in Primary Care (book review), 177

#### PROSPECTIVE REGISTER

Development of a Prospective Register of Smoking Cessation Trials, 235

#### **PROTEINURIA**

Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods (design paper), 442

## QUALITY

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1 Do Low Observed Error Rates Lessen the Need for Study-Specific Data Quality Audits (letter)?, 69

Response to O'Rourke (letter), 71

#### **OUALITY OF LIFE**

Quality of Life and Pharmacoeconomics in clinical Trials (book review), 548

#### **QUANTIFICATION**

A Note on Quantifying Follow-up in Studies of Failure Time, 343

#### RADIATION

Biological Rationale and Clinical Experience with Hyperthermia, 316

#### RANDOM EFFECTS MODEL

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

## RANDOMIZED CONTROLLED TRIALS

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

Maximizing Recruitment Efforts in a Drug Lipid-Lowering Trial with Dietary Intervention to Lower LDL Cholesterol, 33

Randomized Clinical Trials in the Presence of Diagnostic Uncertainty: Implications for Measures of Efficacy and Sample Size, 191

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

Thomas C. Chalmers, M.D., 474
Tribute to Dr. Thomas C. Chalmers, 473
Two Cheers for Bayes (letter), 350, (letter reply), 352

## RANITIDINE

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

## **RATIONALE**

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

#### REACT

Clinical Trial Enrollers vs. Nonenrollers:
The Cardiac Arrhythmia
Suppression Trial (Cast)
Recruitment and Enrollment
Assessment in Clinical Trials
(REACT) Project, 46

#### RECRUITMENT

Communication During the Recruitment

Phase of a Multicenter Trial: The Recruitment Hotline, 415

#### **REGIONAL COORDINATOR**

Remote Clinic/Patient Monitoring for Multicenter Trials, 407

#### **RESEARCH SYNTHESIS**

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

#### RECOMBINANT GROWTH HORMONE

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

## RECRUITMENT

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271

Maximizing Recruitment Efforts in a Drug Lipid-Lowering Trial with Dietary Intervention to Lower LDL Cholesterol, 33

## REGRESSION

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

## REGULATORY-INDUSTRIAL-ACADEMIC PERSPECTIVES

Pharmacokinetics: Regulatory-Industrial-Academic Perspectives (book review), 268

## **RISK STRATIFICATION TRIALS**

Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S

## SAFETY MONITORING

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

## SAMPLE SIZE

Power Calculation for the Log Rank Test Using Historical Data, 111

Randomized Clinical Trials in the Presence of Diagnostic Uncertainty: Implications for Measures of Efficacy and Sample Size, 191

Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

#### **SCREENING**

Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 537

#### SHEP

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271

#### **SIMULATION**

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

## **SIMVASTATIN**

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

## **SMOKING CESSATION TRIALS**

Development of a Prospective Register of Smoking Cessation Trials, 235

#### **STATISTICS**

Statistics in Medical Research: Developments in Clinical Trials (book review), 176

#### STOCHASTIC CURTAILMENT

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526

#### STOPPING RULES

Approaches to Monitoring the Results of

Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

## SUDDEN CARDIAC DEATH

Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrythmias, 17(3S):37S

Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

Sudden Cardiac Death: Lessons from Multicenter Clinical Trials, 17(3S):1S

## **SURVIVAL DATA**

Analyzing Survival Data from Clinical Trials and Observational Studies (book review), 353

Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

## **TARGET**

The Clinical Investigator as Target, 183

#### **THERMORADIOTHERAPY**

Biological Rationale and Clinical Experience with Hyperthermia, 316

#### **THROMBOLYSIS**

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

## **THROMBOSIS**

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992–1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

### TOTAL MORTALITY

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

#### **TREATMENT**

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

#### TRIAL DESIGN

The Economic Avaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS),

Recent Advances in Clinical Trial Design and Analysis (book review), 547

#### TRIAL MANAGEMENT

Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415

#### **VACCINES**

A Factorial Survey Study to Assess the

Acceptability HIV Vaccine Trial Designs, 209

#### **VOLUNTEER STAFF**

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23

Community Volunteers as Recruitment
Staff in a Clinical Trial: The
Systolic Hypertension in the
Elderly Program (SHEP)
Experience (erratum), 271

#### WITHIN-SUBJECT COMPARISONS

Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

## WORLD WIDE WEB (WWW)

A World Wide Web-based User Interface for a Data Management System for Use in Multi-institutional Clinical Trials—Development and Experimental Operation of an Automated Patient Registration and Random Allocation System, 476

## WRITING OF MANUSCRIPTS

Blinding During Data Analysis and Writing of Manuscripts, 285